RxBiologics
RxBiologics is a UK-based antibody discovery CRO offering bespoke services built on its proprietary Galaxy® human antibody library platform, serving pharmaceutical, biotechnology, and academic clients from Cambridge as a subsidiary of RxCelerate.
- Company typePrivate
- Founded2018
- HeadquartersBabraham, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingServices
What RxBiologics does
RxBiologics is a UK-based contract research organisation providing antibody discovery services to pharmaceutical, biotechnology, and academic clients. The company operates from the Babraham Research Campus in Cambridge as a wholly-owned subsidiary of RxCelerate, the drug discovery and development services group founded in 2013, and was itself established in 2018 when RxCelerate partnered with biotech entrepreneur and antibody engineer Jonny Finlay to commercialise the proprietary Galaxy® antibody library platform.
The Galaxy® platform is the company's central technology asset. It is a fully human antibody phage display library constructed using 'smart randomness' for targeted diversification, 'Glass Spleen' B cell-like evolution to access relevant antibody space without excessive mutational load, and controlled light chain diversity for predictable outcomes. The platform is offered on a license-free open access basis, which is positioned as a key differentiator against incumbent display-based CROs. Service offerings span antibody discovery, lead isolation (including high-throughput screening, flow cytometry, and NGS-based diversity interrogation), antibody profiling (ELISA, SPR, BLI, polyreactivity, AC-SINS, functional assays), immune library generation, antibody humanisation and optimisation, in silico analysis, reagent generation, and rapid common light chain bispecifics generation. The Scientific Advisory Board includes co-inventor of clinical-phase antibodies Jonny Finlay and Greg Carven, inventor of pembrolizumab (Keytruda).
The business model is professional services revenue: bespoke, contract-based discovery programmes priced on tailored workflows and deliverables, with no publicly disclosed pricing. Go-to-market is direct, sales-led engagement with enterprise pharmaceutical and biotech clients globally, supported by organic digital presence on LinkedIn, Twitter/X, and YouTube, plus direct email and phone contact. RxBiologics leverages RxCelerate's broader drug discovery infrastructure (biology, in-silico design, chemistry, programme management) to deliver end-to-end preclinical biologics programmes. The company has not raised outside venture capital and is privately held.
RxBiologics firmographics
Firmographics- Name
- RxBiologics
- Legal name
- RxBiologics Ltd
- Website
- https://rxbiologics.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- RxBiologics is a UK-based antibody discovery CRO offering bespoke services built on its proprietary Galaxy® human antibody library platform, serving pharmaceutical, biotechnology, and academic clients from Cambridge as a subsidiary of RxCelerate.
- Ownership category
- akta.pro rank
RxBiologics industry classification
Industry- Product category
- Biologics Drug Discovery Services (Contract Research)
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Preclinical CROs (Discovery/Pharmacology/DMPK) (HLAGAAAB)
Keywords
Where RxBiologics is headquartered
LocationHeadquarters
- HQ city
- Babraham
- HQ country
- United Kingdom
- HQ region
- Europe
Offices1 record
Markets served
RxBiologics business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure
Revenue model
- Contract Research Services: Bespoke CRO services for biologics drug discovery, providing comprehensive work packages from early discovery through preclinical phases. Services include antibody discovery, production, profiling, and humanization delivered on a project/contract basis tailored to client specifications.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
RxBiologics product offering
Product offeringCore offering
RxBiologics operates as a contract research organization (CRO) providing bespoke antibody discovery services built around its proprietary Galaxy® human antibody library platform, which is based on human antibody phage display technology. The company delivers comprehensive biologics drug discovery work packages — including antibody discovery, lead isolation, antibody profiling, immune library generation, antibody humanisation, in silico analysis, reagent generation, and rapid bispecifics generation — to pharmaceutical, biotech and academic clients, supporting programs from early discovery through preclinical phases.
Product overview
RxBiologics is a biologics drug discovery services company offering a platform-plus-services model built around its proprietary Galaxy® antibody library technology. The Galaxy® Platform serves as the core technology, with services including antibody discovery, lead isolation, antibody profiling, immune library generation, antibody humanisation and optimisation, in silico antibody analysis, reagent generation, and rapid bispecifics generation. Services support biologics drug discovery from early discovery through preclinical phases, with the Galaxy® Library enabling delivery of clinic-ready antibodies with drug-like properties in a single-pass process.
Differentiator
Problem solved
Functional benefit
Products and services
- Galaxy® Antibody Library Platform Proprietary human antibody library technology based on human antibody phage display, using smart randomness and Glass Spleen B-cell-like evolution to generate fully human, highly specific, functional and stable antibodies with drug-like properties in a single pass. Provided on a license-free open access basis to clients and partners.
- Antibody Discovery Services Comprehensive antibody discovery service using the proprietary Galaxy® Library to screen antibodies with desired specificity and cross-reactivity. Delivered to pharmaceutical, biotech and academic clients as part of bespoke antibody discovery programs.
- Lead Isolation High-throughput screening service including biochemical assay formats for binding and inhibition, flow cytometry cell-binding analysis, comprehensive sequence analysis, and NGS-based diversity interrogation to identify lead antibody candidates.
- Antibody Profiling Comprehensive profiling service including ELISA, flow cytometry cell binding, SPR affinity measurement, BLI epitope binning, polyreactivity, AC-SINS, functional assays and biophysical analysis of antibody candidates.
- Immune Library Generation Custom build of antibody libraries from immune repertoires for standard and domain antibodies, integrated into the platform drug discovery process to support bespoke antibody programs.
- Antibody Humanisation and Optimisation Humanisation and deimmunisation within CDR regions using in silico design and display technology approaches to generate optimal antibody sequences for therapeutic development.
- In Silico Antibody Analysis Computational services including modelling, structure prediction, developability prediction, immunogenicity prediction, antibody optimisation and humanisation, delivered using licensed in silico software tools.
- Reagent Generation Licensed mammalian cell line services for custom antibody and antigen production, protein purification and QC, and transient cell expression for screening and profiling of antibody reagents.
- Rapid Bispecifics Generation Common light chain bispecific antibody generation capability enabling rapid and cost-effective production of bispecific antibodies without special engineering requirements.
Companies that use RxBiologics
Customer profileSegments3 records
Ideal customer profiles3 records
RxBiologics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
RxBiologics partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- RxCeleratecoreRxCelerate is the parent company of RxBiologics, providing fully integrated or standalone drug discovery and development services for small molecules and biologics. RxBiologics leverages RxCelerate's biology, in-silico design, chemistry, and programme management capabilities to deliver comprehensive biologics drug discovery programmes from early discovery through preclinical phases. RxCelerate was founded in 2013.
Scale indicators1 record
Recent moves5 records
Expansion highlights5 records
RxBiologics competitors and assessment
Company assessmentDirect peers
- GenScript ProBio: GenScript offers antibody discovery services alongside biologics CDMO capabilities, targeting the same pharma/biotech customer base seeking end-to-end biologics development support.
- Adimab: Adimab operates a proprietary yeast-display antibody discovery platform offering outsourced discovery services to pharma and biotech, with a similar platform-plus-services model and 'right first time' ethos.
- BioInvent International: BioInvent is a clinical-stage biotech with a proprietary antibody library platform (n-CoDeR) and offers antibody discovery and development services comparable to RxBiologics' offering.
- ImmunoPrecise Antibodies: ImmunoPrecise provides antibody discovery and characterization services using multiple platforms (phage display, B-cell, hybridoma), serving pharma and biotech clients similar to RxBiologics' customer base.
- AbCellera: AbCellera is a leading antibody discovery CRO that uses single B-cell screening plus AI/ML to deliver fully human antibodies to pharma partners, directly competing for outsourced biologics discovery programs.
Broad incumbents
- WuXi Biologics: WuXi Biologics is a global CRDMO offering antibody discovery, cell line development, and manufacturing services, representing a large-scale competitor for outsourced biologics programs.
- Eurofins Discovery: Eurofins Discovery provides a broad portfolio of CRO services including antibody generation, screening, and characterization, offering comparable antibody discovery capabilities as part of a wider scientific services platform.
- Lonza Biologics: Lonza is a global CDMO with biologics discovery and manufacturing services, offering overlapping antibody discovery capabilities as part of a much larger integrated service portfolio to enterprise pharma clients.
- Charles River Laboratories: Charles River is a large CRO with biologics discovery and development services through its CDMO and discovery segments, competing for similar pharma/biotech contracts at greater scale.
Emerging players
- Trianni (acquired by AbCellera): Trianni offered transgenic mouse antibody discovery platforms competing with phage-display-based approaches; now part of AbCellera, representing an alternative discovery modality in the same market segment.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
RxBiologics social profiles
Digital presenceRxBiologics financial estimates
Financial estimateRevenue estimate
Valuation estimate
RxBiologics leadership team
Management profileNumber of profiles
Profiles6 records
RxBiologics funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
RxBiologics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about RxBiologics
What does RxBiologics do?
RxBiologics operates as a contract research organization (CRO) providing bespoke antibody discovery services built around its proprietary Galaxy® human antibody library platform, which is based on human antibody phage display technology. The company delivers comprehensive biologics drug discovery work packages — including antibody discovery, lead isolation, antibody profiling, immune library generation, antibody humanisation, in silico analysis, reagent generation, and rapid bispecifics generation — to pharmaceutical, biotech and academic clients, supporting programs from early discovery through preclinical phases.
Is RxBiologics a public or private company?
RxBiologics is a private company. It is classified as corporate owned and is currently operating.
When was RxBiologics founded?
RxBiologics was founded in 2018. It employs 11 to 50 people.
Where is RxBiologics based?
RxBiologics is headquartered in Babraham, United Kingdom, in the Europe region.
How does RxBiologics make money?
One revenue line is on record: contract Research Services.
Who are RxBiologics's main competitors?
Direct peers on record are GenScript ProBio, Adimab, BioInvent International, ImmunoPrecise Antibodies and AbCellera. Broad incumbents are WuXi Biologics, Eurofins Discovery, Lonza Biologics and Charles River Laboratories. Trianni (acquired by AbCellera) is listed as an emerging player.
Does RxBiologics have an API?
No public API is recorded for RxBiologics.
What industry is RxBiologics in?
RxBiologics's product category is Biologics Drug Discovery Services (Contract Research). Its primary akta.pro industry code is HLAGAAAB, Preclinical CROs (Discovery/Pharmacology/DMPK). Its NAICS code is 541714 and its SIC code is 8731.